[PDF][PDF] High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies

…, K Takahata, C Seki, Y Takado, H Shinotoh, Y Sano… - Neuron, 2021 - cell.com
A panel of radiochemicals has enabled in vivo positron emission tomography (PET) of tau
pathologies in Alzheimer's disease (AD), although sensitive detection of frontotemporal lobar …

[HTML][HTML] Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy …

…, N Horita, M Wada, S Tsugawa, E Plitman, Y Sano… - Molecular …, 2019 - nature.com
Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of
depression, and the glutamatergic system represents a treatment target for depression. To …

Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies

…, Y Iwabuchi, E Miura, Y Yamamoto, Y Sano… - Brain …, 2021 - academic.oup.com
Tau aggregates represent a key pathologic feature of Alzheimer’s disease and other
neurodegenerative diseases. Recently, PET probes have been developed for in vivo detection of …

Binding of Dopamine D1 Receptor and Noradrenaline Transporter in Individuals with Autism Spectrum Disorder: A PET Study

…, K Takahata, K Matsuoka, K Tagai, Y Sano… - Cerebral …, 2020 - academic.oup.com
Although previous studies have suggested the involvement of dopamine (DA) and noradrenaline
(NA) neurotransmissions in the autism spectrum disorder (ASD) pathophysiology, few …

A Machine Learning–Based Approach to Discrimination of Tauopathies Using [18F]PM‐PBB3 PET Images

…, K Matsuoka, N Kokubo, K Hirata, Y Sano… - Movement …, 2022 - Wiley Online Library
Background We recently developed a positron emission tomography (PET) probe, [ 18 F]PM‐PBB3,
to detect tau lesions in diverse tauopathies, including mixed three‐repeat and four‐…

[HTML][HTML] Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy

…, Y Takado, K Tagai, M Kubota, Y Sano… - Journal of the …, 2023 - Elsevier
Patients with progressive supranuclear palsy (PSP) frequently exhibit apathy but the
neuropathological processes leading to this phenotype remain elusive. We aimed to examine the …

Impact of amyloid and tau PET on changes in diagnosis and patient management

…, Y Iwabuchi, M Kubota, Y Yamamoto, Y Sano… - Neurology, 2023 - AAN Enterprises
Background and Objectives Previous studies have evaluated the diagnostic effect of amyloid
PET in selected research cohorts. However, these studies did not assess the clinical impact …

[HTML][HTML] An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F …

…, K Hirata, H Shinotoh, K Takahata, S Kurose, Y Sano… - Neuroimage, 2022 - Elsevier
Positron emission tomography (PET) with 18 F-PM-PBB3 ( 18 F-APN-1607, 18 F-Florzolotau)
enables high-contrast detection of tau depositions in various neurodegenerative dementias…

PET-based classification of corticobasal syndrome

…, H Shinotoh, S Hirano, K Tagai, Y Sano… - Parkinsonism & Related …, 2022 - Elsevier
Introduction Corticobasal degeneration (CBD) is the most common neuropathological substrate
for clinically diagnosed corticobasal syndrome (CBS), while identifying CBD pathology …

[HTML][HTML] Differential associations of dopamine synthesis capacity with the dopamine transporter and D2 receptor availability as assessed by PET in the living human …

…, M Kubota, H Takano, H Takeuchi, Y Kimura, Y Sano… - Neuroimage, 2021 - Elsevier
Background : The dopamine (DA) neurotransmission has been implicated in fundamental
brain functions, exemplified by movement controls, reward-seeking, motivation, and cognition. …